Pivotal Bio Venture Partners Investment Advisor LLC Vaxcyte, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $71.5 Million
- Q1 2025
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 710,734 shares of PCVX stock, worth $24.4 Million. This represents 37.54% of its overall portfolio holdings.
Number of Shares
710,734
Previous 703,834
0.98%
Holding current value
$24.4 Million
Previous $57.6 Million
53.42%
% of portfolio
37.54%
Previous 53.0%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
345Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$418 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$413 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$404 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$341 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$220 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.04B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...